Examples of using Evaluable in English and their translations into Danish
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
Patients were evaluable for efficacy.
Patienter var evaluerbare for effekt.Partial response Stable disease Progressive disease Not evaluable Unknown.
All evaluable patients engrafted.
The complete molecular response rate was 48% 49 out of 102 evaluable patients.
Den samlede molekylære responsrate var 48% 49 ud af 102 evaluerbare patienter.Eight of 13 evaluable patients were shown to possess neutralizing antibodies.
Otte ud af 13 evaluérbare patienter viste sig at have neutraliserende antistoffer.In ASPIRE, more than 90% of patients had at least two evaluable X-rays.
I ASPIRE havde mere end 90% af patienterne mindst to bedømmelsesværdige røntgenbilleder.A total of 74 evaluable patients were administered dexamethasone in combination with VELCADE.
I alt har 74 vurderbare patienter fået dexamethason sammen med VELCADE.At the start virtually all patients are evaluable PFS patients in the trial.
Som det startes med at fortælles er stort set alle patienter evaluerbare PFS patienter i forsøget.Eighteen were evaluable for efficacy and safety and a further five patients were evaluable for toxicity only.
Atten var evaluerbare for effekt og sikkerhed og yderligere fem patienter var kun evaluerbare for toksicitet.Only attributes are basically fully evaluable, that must be entered as a mandatory.
Kun attributterne er dybest set fuldt evaluable, der skal angives som et obligatorisk.Thirty-two(32) evaluable paediatric patients crossed over 9 subjects in the q8 weeks and 23 subjects in the q12 weeks maintenance groups.
Toogtredive(32) evaluerbare patienter crossed over 9 personer i 8. ugers gruppen og 23 i 12 ugers gruppen.Of the three study groups, 16, 19 and28 patients respectively had evaluable baseline isolates and subsequently remained in the study for at least 24 weeks.
I de tre studier,havde respektivt 16, 19 og 28 patienter evaluerbare baseline isolater og blev derfor i studiet i mindst 24 måneder.Corrected for multiple comparisons and adjusted for stratification factors(stage of disease and region of treatment),based on evaluable patient population.
Rettet for multible sammenligninger og justeret for stratification faktorer(stadie af sygdommen og behandlingsregion),baseret på beregnelig patientpopulation.Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults twelve children over 12 years, nine children between 6 and 12 years.
Af de 23 børn var 21 evaluérbare med hensyn til farmakokinetisk sammenligning med voksne 12 børn over 12 år, 9 børn mellem 6 og 12 år.Pharmacokinetics in adults Absorption The pharmacokinetics of intravenous busulfan was studied in 124 evaluable patients following a 2- hour intravenous infusion for a total of 16 doses over four days.
Pharmakokinetik for voksne Absorption Farmakokinetikken for intravenøst busulfan blev undersøgt hos 124 evaluerbare patienter efter 2 timers intravenøs infusion af i alt 16 doser i løbet af 4 dage.Out of the 411 patients, 353 were treated in an expanded access program without primary response data collected. The median time to progression in the overall population of 411 patients with relapsed/ refractory Ph+ ALL ranged from 2.6 to 3.1 months, andmedian overall survival in the 401 evaluable patients ranged from 4.9 to 9 months.
Mediantid før progression varierede i den samlede population af 411 patienter med recidiverende/ refraktær Ph+ ALL fra 2,6 til 3, 1 måned, og median for samlet overlevelse hos de 401 evaluerbare patienter varierede fra 4, 9 til 9 måneder.Patients with≥ one dose of study drug with evaluable baseline liver biopsies and baseline Knodell Histological Activity Index(HAI) score> 3.
Patienter med> én dosis testmedicin med vurderbare leverbiopsier ved forsøgsstart og Knodells histologiske aktivitetsindeks(HAI)- score> 3 ved forsøgsstart.An evaluation of potential clinical impact of LeukoScan demonstrated that LeukoScan could change clinical management in 50.2% orimprove clinical outcome in 43.4% of the 175 evaluable patients with suspected osteomyelitis.
En vurdering af LeukoScans potentielle kliniske betydning viste, at LeukoScan kunne ændre denkliniske behandling i 50, 2% eller forbedre det kliniske resultat i 43, 4% af de 175 evaluerbare patienter med mulig osteomyelitis.At the start virtually all patients are evaluable PFS patients in the trial. TopoTarget hadto have 68 PFS events(or 75% of patients PFS event) in order to break the code.
Som det startes med at fortælles er stort set alle patienter evaluerbare PFS patienter i forsøget. Topo har således skulle have 68 PFS events eller 75% af patienters PFS event indtruffen for at koden kunne brydes.Imatinib in combination with chemotherapy induction(see Table 5)resulted in a complete haematological response rate of 93%(147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% 19 out of 21 evaluable patients.
Imatinib givet i kombination medkemoterapi- induktion(se Tabel 5) resulterede i en komplet hæmatologisk responsrate på 93%(147 ud af 158 evaluerbare patienter), og i en væsentlig cytogenetisk responsrate på 90% 19 ud af 21 evaluerbare patienter.In a secondary analysis,which utilised DRC assessments at the latest evaluable time point(EOT, or 2, 6, or 12 weeks after EOT) voriconazole and the regimen of amphotericin B followed by fluconazole had successful response rates of 65% and 71%, respectively.
I en anden analyse,hvor DRCs vurderinger anvendes ved det seneste evaluerbare tidspunkt(EOT eller 2, 6 eller 12 uger efter EOT) havde voriconazol og amphotericin B efterfulgt af fluconazol en succesfuld responsrate på henholdsvis 65% og 71.REYATAZ/ RTV with tenofovir/ emtricitabine(fixed dose 300 mg/ 200 mg tablets once daily). b Lopinavir/ RTV with tenofovir/ emtricitabine(fixed dose 300 mg/ 200 mg tablets once daily). c Intent-to-treat analysis,with missing values considered as failures. d Number of patients evaluable.
REYATAZ/ RTV med tenofovir/ emtricitabin(fast dosis på 300 mg/ 200 mg tabletter én gang dagligt). b Lopinavir/ RTV med tenofovir/ emtricitabin(fast dosis på 300 mg/ 200 mg tabletter én gang dagligt). c ITT- analyse(Intent- to- treat),hvor manglende værdier anses som svigt. d Antal evaluerbare patienter.The modified intent to treat population was defined as all patients randomised to study medication who also had evaluable seizure diaries available for 28 days during both the baseline and double-blind phases.
Den modificerede” intent to treat” population er defineret som alle patienter, der er randomiseret til forsøgsmedicin, og som også har evaluerbar dagbog over anfald tilgængelig i alle 28 dage under både baseline og dobbelt- blind faserne.Genotypic analysis of 203 evaluable sample pairs with HBV DNA≥ 1,000 copies/ ml at week 104 demonstrated that the primary mutation associated with telbivudine resistance was rtM204I, often associated with mutations rtL180M and rtL80I/ V and infrequently with rtV27A, rtL82M, rtV173L, rtT184I and rtA200V.
Genotypisk analyse af 203 vurderbare prøvepar med HBV DNA≥ 1000 kopier/ ml i uge 104 viste, at den primære mutation, som var forbundet med telbivudinresistens, var rtM204I ofte forbundet med mutationerne rtL180M og rtL801/ V og sjældent med mutationerne rtV27A, rtL82M, rtV173L, rtT184I og rtA200V.When imatinib was used as single agent in patients with relapsed/ refractory Ph+ ALL, it resulted, in the 53 out of 411 patients evaluable for response, in a haematological response rate of 30%(9% complete) and a major cytogenetic response rate of 23.
Da imatinib blev brugt som enkeltstofbehandling ved recidiverende/ refraktær Ph+ ALL var resultatet hos 53 ud af 411 evaluerbare patienter en hæmatologisk responsrate på 30%(9% komplet) og en væsentlig cytogenetisk responsrate på 23.Although transplantation rate was not a study endpoint, 10/ 61 patients(16%) went on to receive a HSCT after treatment with clofarabine 3 after achieving a CR, 2 after a CRp, 3 after a PR, 1 patient that was considered a treatment failure by the IRRP and1 that was considered not evaluable by the IRRP.
Selv om forekomst af transplantationer ikke var et af forsøgets endepunkter, fik 10/ 61 patienter(16%) HSCT efter behandling med clofarabin af disse havde 3 opnået CR og 2 CRp, 3 havde opnået PR, 1 patient blev af IRRP henregnet under behandlingssvigt, og1 blev af IRRP anset for ikke- evaluerbar.Of evaluable patients treated with ertapenem in a clinical study for the treatment of intra- abdominal infections, in adults, 30% had generalized peritonitis and 39% had infections involving sites other than the appendix including the stomach, duodenum, small bowel, colon, and gallbladder; there were limited numbers of evaluable patients who were enrolled with APACHE II scores≥ 15 and efficacy in these patients has not been established.
Evaluerbare patienter behandlet med ertapenem i en klinisk undersøgelse af behandling af intra- abdominale infektioner, hos voksne, havde 30% af disse generaliseret peritonitis og 39% havde infektioner, der involverede andre positioner end appendiks, inkluderende mave, duodenum, tyndtarm, colon og galdeblære; der var et begrænset antal evaluerbare patienter med APACHE II scores ≥ 15, og effekt hos disse patienter er ikke påvist.
